je.st
news
Tag: percent
REITs Up 0.2 percent in First Month of 2017
2017-02-02 14:45:00| National Real Estate Investor
Sarah Borchersen-Keto REITs made modest gains in January, as investors continued to size up potential changes to the macroeconomic environment, market watchers said. read more
Farmers Receive Less Than Twenty Percent of Thanksgiving Retail Food Dollar, NFU Farmers Share Shows
2016-11-21 15:00:39| National Farmers Union
FOR IMMEDIATE RELEASE November 21, 2016 Contact: Andrew Jerome, 202-314-3106 ajerome@nfudc.org WASHINGTON (November 21, 2016) Consumers holiday food costs have declined, but farmers still receive less than 20 percent of the food dollar, according to the annual Thanksgiving edition of the National Farmers Union (NFU) Farmers Share publication. The popular Thanksgiving Farmers Share compares […]
Tags: share
receive
food
shows
Study reveals 82 percent of the core ecological processes are now affected by climate change
2016-11-14 13:00:00| LifeSciencesWorld
[NEWS] Most studies of global climate change attempt to predict what might happen to the Earth as temperatures rise in future. A new study representing an international collaboration by ecologists and conservation biologists shows that global changes in climate have already impacted every aspect of life on Earth, from genes to entire ecosystems. It was published in the prestigious journal Science on November 10, 2016. The research team, led by the University of Florida and with participation from…
Tags: change
study
core
percent
Google Express Now Covers 90 Percent of US
2016-10-26 22:03:35| PC Magazine Software Product Guide
Rival AmazonFresh, meanwhile, announced its expansion into two new cities.
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] next »